CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
CG Oncology 將在 ASCO 2024 年年會上公佈 Cretostimogene Grenadenorepvec 與 Pembrolizumab 聯合應用於 BCG 無反應的高風險 NMIBC 的 2 期 CORE-001 研究的最終結果
CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
CG Oncology 將在 ASCO 2024 年年會上公佈 Cretostimogene Grenadenorepvec 與 Pembrolizumab 聯合應用於 BCG 無反應的高風險 NMIBC 的 2 期 CORE-001 研究的最終結果
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。